Unicycive gains on promising data from kidney disease drug's pre-clinical study

Unicycive Therapeutics

07/09/2022 13:56

** Shares of Unicycive Therapeutics Inc  UNCY.O  rise ~7% to
$0.76 premarket
    ** Co says its drug candidate UNI-494 for treating acute
kidney injury showed reduction in levels of a type of kidney
function markers in a pre-clinical study on rats  urn:newsml:reuters.com:*:nGNX9B3jRg
    ** Says it is on track to file a regulatory submission by
end-2022 for initiating an early-stage study of the drug
    ** Acute kidney injury is a condition in which kidneys
suddenly stop working properly
    ** As of last close, stock down 65.5% YTD

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))